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What’s onco-nephro?

Acute renal failure
• Pre-renal
• Volume depletion
• Vomiting, diarrhea, sepsis
• Meds: diuretics, NSAIDs, ACE, ARB, etc.

• Hypercalcemia- natriuresis and vasoconstriction
• PTH related protein production-promotes liberation of Ca from bone
• SCC of lung, cervix, and esophagus, lymphomas, RCC, and adenocarcinoma of
breast, prostate, ovary
• Bone metastases- mobilize Ca and osteoclasts
• Myeloma, breast and lung metastases
• Expression of 1-alpha hydroxylase leading to conversion of 25-OH vit D to calcitriol
• Hodgkin’s and Non-Hodgkin’s
• Treatment- Volume, Bisphosphonates, Donosumab, rarely steroids

Acute renal failure
• Pre-renal (cont.)
• Hepatic Sinsusoidal Obstruction Syndrome
• Complication of hematopoietic cell transplantation (HCT)
• Acute radiochemotherapy induced damage to sinusoidal hepatocytes
leading to thrombosis and portal hypertension
• Similar physiology to hepato-renal but 70% will recover with
supportive care

• Calcineurin inhibitors
• Used in prevention of GVHD, e.g. tacrolimus, cyclcosporine
• Can cause both dose dependent AKI and CKD

Acute renal failure
• Intrinsic
• Glomerular (paraneoplastic syndromes)
• Membranous GN(GVHD, solid tumor malignancy)
• 5-25% related to malignancy
• Can be idiopathic or malignancy associated, in 2009 Beck et al found
circulating PLA2R Ab in those w idiopathic disease; 75% of those w
idiopathic disease are +….remaining need age-appropriate cancer
screening
• Minimal Change Disease (hematologic malignancies)
• IgA nephropathy (RCC)
• FSGS, HSP, ANCA vasculitis, AA amyloid (more studies needed to illustrate
relationship)
• Lymphomatous infiltration of the kidney

Acute renal failure
• Intrinsic
• Tubulointerstitial
• Cast Nephropathy (15-40% of myeloma pts), requiring acute dialysis at
diagnosis (10%)
• Survival significantly shorter in those with renal failure
• Clonal free light chains overwhelm the proximal tubule so they
continue to the distal tubule where they bind to Tamm Horsefall
protein and create tubular obstruction
• Renal recovery appears to be time sensitive, prompt treatment key

Plasmapheresis

Brenner and Rector’s The
Kidney, 8th ed. 2071-2080,
2007.

Plasmapheresis at SJMC

Acute renal failure
• Intrinsic
• Tumor lysis syndrome
• Occurs after the treatment of lg volume malignancies, usually
hematologic, some solid tumor as well, occasionally even before
treatment
• Occurs when intracellular contents overwhelm excretion of the body
• Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia,
hallmarks
• Uric acid is the main concern causing injury that can prolong
• Treatments include allopurinol, febuxostat and rasburicase

Acute renal failure
• Intrinsic
• Thrombotic microangiopathy
• Results from platelet activation and formation of thrombi with
subsequent vessel wall swelling and necrosis
• Forms include cancer-associated and hematopoietic cell transplantationassociated

Acute renal failure
• Post-renal
• Obstruction- most common in bladder, uterine and prostate
cancers
•
•
•
•

Tumor obstruction
Lymphatic obstruction
Retroperitoneal fibrosis (radiation-induced vs malignancy itself)
Treated with nephrostomy vs ureteral stent

Kitai Y et al. Onco-nephrology:
Current concepts and future
perspectives. Japanese Journal
of Clinical Oncology, 2015 45(7)
617-628.

Chemotherapy in CKD
• Most chemo is renally excreted but data on renal/dialysis clearance is incomplete
• Excretion in general is of cytotoxic metabolites so delays in elimination can lead
to toxicity/overdose
• Also chemo exacerbates chronic conditions like renal anemia, infection risks
• Glomerular filtration and hemodialysis play an important role in clearance of nonprotein bound molecules (e.g. carboplatin, can be cleared in dialysis pts if timed
well but after 24h, protein-binding increases leading to toxicity)
• Tyrosine kinase inhibitors generally safer as cleared by the liver but still a study on
sorafenib saw far more bleeding events in dialysis patients due to more
vulnerable vasculature

Cancer risk in CKD
• In CKD pts impaired immune system, decreased antioxidant defense, accumulation of
carcinogens due to impaired clearance, chronic infection and inflammation all increase
cancer risk
• Uremic toxins also increase risk of viral mediated cancers
• Chronic dialysis suppressed DNA repair activity of lymphocytes and also associated w
glutathione perioxidase deficiency
• Cystic kidney diseases increase the risk of kidney cancers
• Thyroid cancers are higher during dialysis and after transplant
• CKD pts treated with cyclophosphamide, azathioprine, other immunosuppressives, all
inc risk
• However large retrospective studies have not necessarily isolated these differences
cancer rates in dialysis patients, possible due to reduced screening and high
cardiovascular mortality

Screening for cancer in ESRD
• Cost per unit of survival benefit may be 20x higher in dialysis patients
• A typical screening program may have a net gain in life expectancy of 5 days or
less amongst a dialysis cohort
• Most societies recommend continuing screening in dialysis patients for those on a
transplant waiting list but age cutoffs vary
• Renal cell carcinoma is not screened for in the general population but in those on
dialysis 3 years or more aged 20 a 1.6 year survival benefit was suggested if
screened every 3 years

Screening for cancer post transplantation

Holley, J. Cancer screening in ESRD. Onco-nephrology curriculum.
American Society of Nephrology, 2016.
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